Head-to-head evidence
fluticasone furoate/vilanterol vs Proventil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
fluticasone furoate/vilanterol
Marketed by GlaxoSmithKline
NCT01086384 · Phase 3 · completed
This was a randomized, triple-blind, active-controlled trial with approximately 2,019 treated participants. Its primary hard clinical endpoint—having one or more severe asthma exacerbations—favored fluticasone furoate/vilanterol and was statistically significant.
Proventil
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00577655 · Phase 3 · completed
The trial randomized 103 children to albuterol or placebo and masked participants, caregivers, investigators, and outcome assessors. Its primary measures were physiologic lung-function outcomes rather than hard clinical outcomes; the FEV1 comparison was statistically significant, while the PEF comparison was not significant at the prespecified threshold, so the findings were mixed.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/vilanterol's landscape · Proventil's landscape